ARG is dedicated to efficiently and effectively supporting small and mid-size biotech and pharmaceutical companies through the challenging clinical trial process.
We've relied upon our experience to create TrialVista® - the most innovative clinical trial management software solution available - which enables us to better manage the dynamic requirements of bringing molecules to market.Find out more
Pivotal Phase III Trial Undergoes Audits by the FDA and Sponsor
A pivotal Phase III clinical trial of C1 inhibitor for the prophylactic treatment of hereditary angioedema managed by ARG successfully underwent 3 investigative site audits by the FDA and a complete audit by our sponsor. The BLA submission for C1 inhibitor has been made to the FDA and approval was granted in 2008.Find out more
ARG Successfully Starts Up A Phase II Trial Within 6 Weeks
In an economic downturn, small biotech companies often depend on clinical milestones in order to maximize shareholder value and drive market direction. This means that their CRO must completely understand and be aligned with the sponsor's corporate objectives. Meeting an aggressive timeline on a challenging protocol is a significant driver of share price and market perception.Find out more